MAY 24·fool.com▼
Looking to Buy Bristol Myers Squibb Stock on the Dip? Read This First.
Bristol Myers Squibb (BMY) shares have rebounded after falling about 11% and remain below an early-March YTD peak, trading at a forward P/E of 9.4. The article cites risks including Revlimid revenue decline from generic competition and loss of U.S. patent exclusivity for Eliquis and Opdivo in 2028, plus acquisition and integration/clinical risks. It notes growth drugs are most revenue, while legacy drugs are ~46% and revenue rose ~1% constant-currency.
MAY 24·Simply Wall Street→
How Bristol Myers Squibb’s Claude AI Deployment Across its Pipeline (BMY) Has Changed Its Investment Story
Bristol Myers Squibb has partnered with Anthropic to widely deploy Claude AI across its R&D, clinical development, manufacturing, commercial, and corporate functions, along with a separate AI collaboration with Tempus AI for clinical trial design. This strategic move aims to accelerate drug development and operational workflows. While the company faces looming patent cliffs and pricing pressure, the AI integration could modestly influence execution on late-stage oncology and immunology launches and potentially reinforce optimistic margin forecasts, though investors must still monitor intensifying market headwinds and trial outcomes.
